Ceribell, Inc. (CBLL)
NASDAQ:CBLL
Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$18.36
-$0.15(-0.64%)
At close: 4:00 PM EST
$18.36
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.85 - $24.33
Previous CloseN/A
Volume46.56K
Average Volume (3M)265.67K
Market Cap
$776.39M
Enterprise Value$758.19M
Total Cash (Recent Filing)$159.26M
Total Debt (Recent Filing)$22.28M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 07, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.47
Shares Outstanding37,872,490
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue8.51
Enterprise Value/Gross Profit9.69
Enterprise Value/Ebitda-15.02
Forecast
1Y Price Target
$29.00Price Target Upside57.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$112.67M
Bulls Say, Bears Say
Bulls Say
Commercial Traction And Account GrowthReported revenue beats and a record increase in active accounts point to accelerating adoption across community and tertiary hospitals, with expanded sales coverage and targeted large system signings expected to drive further sales.
Product Differentiation And Clinical NeedAnalyst notes the AI-driven point-of-care EEG is the first to combine seizure detection and delirium screening across ages, addressing widespread gaps in continuous bedside monitoring and encouraging hospital uptake.
Regulatory Approvals Expand MarketAnalyst highlights FDA clearances for neonatal and delirium algorithms enable commercialization in neonatal and pediatric care, substantially expanding the addressable market for bedside seizure and delirium monitoring.
Bears Say
Conservative Guidance Limits UpsideAnalyst reduced the price target modestly after management issued guidance that closely aligns with current expectations, creating downside risk if commercial momentum slows or fails to exceed guidance.
Rising Operating Expenses Weigh On ProfitabilityHigher operating expenses driven by salesforce investments, increased headcount, legal fees, and public company costs pressure near-term profitability despite stronger revenue trends.
Sourcing-related Margin PressureA shift toward lower-cost product sourcing may put pressure on gross margins and could dilute some benefits from diversified manufacturing.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $24.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $776.39M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is May 07, 2026 which is in 3 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on Feb 24, 2026. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.052.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,872,490 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -4.774%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (57.95% Upside)
$29.00 (57.95% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 533.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
-31.77%
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
CBLL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong growth story highlighted by double‑digit revenue increases (Q4 +34%, full year +36%), high gross margins (~87%–88%), important regulatory clearances (neonatal/pediatric seizure, delirium 510(k), LVO Breakthrough Device), FedRAMP High approval and an expanded TAM (~$3.5B). These operational and regulatory milestones, plus a solid cash position ($159M), provide a foundation for continued expansion. Counterbalancing these positives are elevated operating expenses (+42% YoY), an increased full-year net loss ($53.4M), tariff-driven margin pressure and near-term litigation costs tied to ITC proceedings. Management’s 2026 guidance is conservative (25%–29% growth) with modest near-term revenue contribution expected from new indications due to sales-cycle timing. On balance, the call emphasized sustained execution and sizable long-term opportunity while acknowledging expected short-term costs and timing risks.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$29.00
▲(57.95% Upside)
Technical Analysis
Ownership Overview
16.57% Insiders
22.94% Mutual Funds
6.85% Other Institutional Investors
46.46% Public Companies and
Individual Investors